Trial Profile
Prospective Evaluation of a Continuation Therapy With Midostaurin in Adult Patients With Core-binding Factor Leukemia and Integrated Genetic Analysis: a Multi-center Phase II Study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Nov 2023
Price :
$35
*
At a glance
- Drugs Midostaurin (Primary) ; Cytarabine; Daunorubicin; Idarubicin
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms AML FLT3
- 21 Mar 2023 Planned primary completion date changed from 31 Mar 2022 to 30 Jun 2023.
- 13 Dec 2022 Preliminary results assessing clonal evolution of CBFLs, NGS and MRD status (performed by qPCR and high-resolution multicolor flow cytometry) were assessed at established check-points during consolidation, maintenance therapy, and at relapse presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 08 Dec 2020 Interim Results (n=17) presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology